NicOx S.A. - Product Pipeline Review - 2016

  • ID: 3837873
  • Company Profile
  • 61 pages
  • Global Markets Direct
1 of 4
NicOx S.A. - Product Pipeline Review - 2016

Summary

‘NicOx S.A. - Product Pipeline Review - 2016’, provides an overview of the NicOx S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NicOx S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of NicOx S.A.
- The report provides overview of NicOx S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses NicOx S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features NicOx S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate NicOx S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for NicOx S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NicOx S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

NicOx S.A. Snapshot

NicOx S.A. Overview

Key Information

Key Facts

NicOx S.A. - Research and Development Overview

Key Therapeutic Areas

NicOx S.A. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

NicOx S.A. - Pipeline Products Glance

NicOx S.A. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Filing rejected/Withdrawn Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

NicOx S.A. - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

NicOx S.A. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

NicOx S.A. - Drug Profiles

cetirizine hydrochloride

Product Description

Mechanism of Action

R&D Progress

naproxcinod

Product Description

Mechanism of Action

R&D Progress

azithromycin

Product Description

Mechanism of Action

R&D Progress

bromfenac sodium

Product Description

Mechanism of Action

R&D Progress

fluticasone propionate

Product Description

Mechanism of Action

R&D Progress

cerdulatinib

Product Description

Mechanism of Action

R&D Progress

ISV-405

Product Description

Mechanism of Action

R&D Progress

NCX-1021

Product Description

Mechanism of Action

R&D Progress

NCX-1653

Product Description

Mechanism of Action

R&D Progress

NCX-250

Product Description

Mechanism of Action

R&D Progress

NCX-422

Product Description

Mechanism of Action

R&D Progress

NCX-429

Product Description

Mechanism of Action

R&D Progress

NCX-434

Product Description

Mechanism of Action

R&D Progress

NCX-466

Product Description

Mechanism of Action

R&D Progress

NCX-470

Product Description

Mechanism of Action

R&D Progress

NCX-667

Product Description

Mechanism of Action

R&D Progress

NicOx S.A. - Pipeline Analysis

NicOx S.A. - Pipeline Products by Target

NicOx S.A. - Pipeline Products by Route of Administration

NicOx S.A. - Pipeline Products by Molecule Type

NicOx S.A. - Pipeline Products by Mechanism of Action

NicOx S.A. - Recent Pipeline Updates

NicOx S.A. - Dormant Projects

NicOx S.A. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

naproxcinod

NCX-1000

NCX-1236

NCX-226

NCX-285

NCX-6560

NicOx S.A. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

NicOx S.A., Key Information

NicOx S.A., Key Facts

NicOx S.A. - Pipeline by Indication, 2016

NicOx S.A. - Pipeline by Stage of Development, 2016

NicOx S.A. - Monotherapy Products in Pipeline, 2016

NicOx S.A. - Partnered Products in Pipeline, 2016

NicOx S.A. - Partnered Products/ Combination Treatment Modalities, 2016

NicOx S.A. - Pre-Registration, 2016

NicOx S.A. - Filing rejected/Withdrawn, 2016

NicOx S.A. - Phase III, 2016

NicOx S.A. - Phase I, 2016

NicOx S.A. - Preclinical, 2016

NicOx S.A. - Pipeline by Target, 2016

NicOx S.A. - Pipeline by Route of Administration, 2016

NicOx S.A. - Pipeline by Molecule Type, 2016

NicOx S.A. - Pipeline Products by Mechanism of Action, 2016

NicOx S.A. - Recent Pipeline Updates, 2016

NicOx S.A. - Dormant Developmental Projects,2016

NicOx S.A. - Discontinued Pipeline Products, 2016

NicOx S.A., Subsidiaries 59List of Figures

NicOx S.A. - Pipeline by Top 10 Indication, 2016

NicOx S.A. - Pipeline by Stage of Development, 2016

NicOx S.A. - Monotherapy Products in Pipeline, 2016

NicOx S.A. - Partnered Products in Pipeline, 2016

NicOx S.A. - Pipeline by Top 10 Target, 2016

NicOx S.A. - Pipeline by Route of Administration, 2016

NicOx S.A. - Pipeline by Molecule Type, 2016

NicOx S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll